Australia's 4DMedical jumps on US FDA approval
** Shares of 4DMedical 4DX.AX up 20.6% to A$0.79, set for
best day since Nov. 13, if gains hold
** Medical technology firm says it has received clearance
for its computed tomography-based ventilation product CT LVAS
from the U.S. Food and Drug Administration (FDA)
** Says, FDA clearance expands patient accessibility of
functional lung imaging in the U.S.
** 4DX stock up ~56% YTD as of last close
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on 4DMedical
See all newsBrief: 4Dmedical Receives TGA Approval For CTVQ In Australia
Brief: 4Dmedical Launches Clear Clinical Evidence Program
Brief: 4Dmedical Creates EU Platform Via Contextflow Acquisition
Australia's 4DMedical rises on establishing European platform via acquisition
Brief: 4Dmedical Says CT:VQ Enters US Outpatient Market Via Simonmed's 170-Site Network